Phase 1 Multiple Ascending Dose Study of Elotuzumab (BMS-901608) in Combination With Lenalidomide/Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma in Japan.
Phase of Trial: Phase I
Latest Information Update: 17 Feb 2018
At a glance
- Drugs Elotuzumab (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 19 Apr 2017 Status changed from active, no longer recruiting to completed.
- 06 Jul 2015 Planned End Date changed from 1 Aug 2015 to 1 Aug 2016 as per ClinicalTrials.gov record.
- 23 May 2015 Planned number of patients changed from 20 to 6 as reported by ClinicalTrials.gov record.